Isotypes of Epstein-Barr virus antibodies in rheumatoid arthritis: Association with rheumatoid factors and citrulline-dependent antibodies

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Westergaard, Marie Wulff ^a   Draborg, Anette Holck ^a   Troelsen, Lone ^b   Jacobsen, Søren ^b   Houen, Gunnar ^a   Pan, Hai Feng ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b University of Copenhagen   (Denmark)

^c Department of Rheumatology Rigshospitalet Copenhagen University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR; VIRUS ANTIBODY; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN-BARR VIRUS EARLY ANTIGEN; IMMUNOGLOBULIN CLASS; METHOTREXATE; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VERY ELDERLY; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; VIROLOGY; YOUNG ADULT;

HUMAN HERPESVIRUS 4;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ARTHRITIS, RHEUMATOID; CITRULLINE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN ISOTYPES; MALE; METHOTREXATE; MIDDLE AGED; RHEUMATOID FACTOR; YOUNG ADULT;

EID: 84929377528     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/472174     Document Type: Article

References (46)

1. E.Myasoedova, J.M.Davis III, C. S. Crowson, and S. E. Gabriel, "Epidemiology of rheumatoid arthritis: rheumatoid arthritis andmortality, " Current Rheumatology Reports, vol. 12, no. 5, pp. 379-385, 2010.
2. M. Pedersen, S. Jacobsen, P. Garred et al., "Strong combined gene-environment effects in anti-cyclic citrullinated peptidepositive rheumatoid arthritis: a nationwide case-control study in Denmark, " Arthritis & Rheumatism, vol. 56, no. 5, pp. 1446-1453, 2007.
3. K. H. Costenbader and E. W. Karlson, "Epstein-Barr virus and rheumatoid arthritis: is there a link?" Arthritis Research and Therapy, vol. 8, article 204, 2006.
4. H. H. Niller, H. Wolf, and J. Minarovits, "Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases, " Autoimmunity, vol. 41, no. 4, pp. 298-328, 2008.
5. W. Amon and P. J. Farrell, "Reactivation of Epstein-Barr virus fromlatency, " Reviews inMedicalVirology, vol. 15, no. 3, pp. 149-156, 2005.
6. A. H. Draborg, J. M. Jørgensen, H. Müller et al., "Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients, " Scandinavian Journal of Rheumatology, vol. 41, no. 4, pp. 280-289, 2012.
7. Q. Zhang, E. Holley-Guthrie, D.Dorsky, and S. Kenney, "Identification of transactivator and nuclear localization domains in the Epstein-Barr virus DNA polymerase accessory protein, BMRF1, "The Journal of General Virology, vol. 80, no. 1, pp. 69-74, 1999.
8. W. Hinderer, D. Lang, M. Rothe, R. Vornhagen, H. H. Sonneborn, and H. Wolf, "Serodiagnosis of Epstein-Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion, " Journal of Clinical Microbiology, vol. 37, no. 10, pp. 3239-3244, 1999.
9. É. Toussirot and J. Roudier, "Epstein-Barr virus in autoimmune diseases, " Best Practice and Research: Clinical Rheumatology, vol. 22, no. 5, pp. 883-896, 2008.
10. M. A. Alspaugh, G. Henle, E. T. Lennette, and W. Henle, "Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis, " The Journal of Clinical Investigation, vol. 67, no. 4, pp. 1134-1140, 1981.
11. P. B. Ferrell, C. T. Aitcheson, G. R. Pearson, and E. M. Tan, "Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis, " The Journal of Clinical Investigation, vol. 67, no. 3, pp. 681-687, 1981.
12. M. McDermott, M. Molloy, J. Buckley, and J. Greally, "Antibodies to Epstein-Barr viral antigens in familial rheumatoid arthritis, " Irish Journal of Medical Science, vol. 158, no. 8, pp. 203-205, 1989.
13. M. Mousavi-Jazi, L. Boström, C. Lövmark, A. Linde, M. Brytting, and V.-A. Sundqvist, "Infrequent detection of cytomegalovirus and Epstein-Barr virus DNA in synovial membrane of patients with rheumatoid arthritis, " Journal of Rheumatology, vol. 25, no. 4, pp. 623-628, 1998.
14. J. D. Lünemann, O. Frey, T. Eidner et al., "Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis, " Journal of Immunology, vol. 181, no. 2, pp. 991-1000, 2008.
15. D. Aletaha, T. Neogi, A. J. Silman et al., "2010 Rheumatoid arthritis classification criteria: an AmericanCollege ofRheumatology/European League Against Rheumatism collaborative initiative, " Arthritis & Rheumatology, vol. 62, pp. 2569-2581, 2010.
16. M. C. Hochberg, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, " Arthritis and rheumatism, vol. 40, article 1725, 1997.
17. A. H. Draborg, S. Jacobsen, M. Westergaard et al., "Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients, " Lupus Science & Medicine, vol. 1, no. 1, Article ID e000015, 2014.
18. L. N. Troelsen, P. Garred, B. Christiansen et al., "Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis, " Molecular Immunology, vol. 47, no. 4, pp. 713-718, 2010.
19. M. Høier-Madsen, L. P. Nielsen, and S. Møller, "Determination of IgM rheumatoid factors by enzyme-linked immunosorbent assay (ELISA), " DanishMedical Bulletin, vol. 148, pp. 2018-2021, 1986.
20. L. Frappier, "TheEpstein-Barr virus EBNA1 protein, " Scientifica, vol. 2012, Article ID438204, 15 pages, 2012.
21. F. Chen, J.-Z. Zou, L. Di Renzo et al., "A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1, " Journal of Virology, vol. 69, no. 6, pp. 3752-3758, 1995.
22. R. D. Hess, "Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years, " Journal of Clinical Microbiology, vol. 42, no. 8, pp. 3381-3387, 2004.
23. T. J. Kindt, R. A. Goldsby, B. A. Osborne, and J. Kuby, Immunology, W.H. Freeman, New York, NY, USA, 6th edition, 2007.
24. O. H. Brekke and I. Sandlie, "Therapeutic antibodies for human diseases at the dawn of the twenty-first century, " Nature Reviews Drug Discovery, vol. 2, no. 1, pp. 52-62, 2003.
25. K. P.Murphy, C. A. Janeway, P. Travers, M. Walport, A. Mowat, and C. T. Weaver, Janeway's Immunobiology, Garland Science, London, UK, 8th edition, 2012.
26. M. Zhang and P. Coffino, "Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing, " Journal of Biological Chemistry, vol. 279, no. 10, pp. 8635-8641, 2004.
27. R. Fåhraeus, "Do peptides control their own birth and death?" Nature ReviewsMolecular Cell Biology, vol. 6, no. 3, pp. 263-267, 2005.
28. T. Klatt, Q. Ouyang, T. Flad et al., "Expansion of peripheral CD8+ CD28-T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis, " The Journal of Rheumatology, vol. 32, no. 2, pp. 239-251, 2005.
29. A. Ichikawa, F. Arakawa, J. Kiyasu et al., "Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression, " European Journal of Haematology, vol. 91, no. 1, pp. 20-28, 2013.
30. K.Matsuo, Y. Xiang, H.Nakamura et al., "Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach, " Arthritis Research and Therapy, vol. 8, article R175, 2006.
31. Y. Takizawa, A. Suzuki, T. Sawada et al., "Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids, " Annals of the Rheumatic Diseases, vol. 65, no. 8, pp. 1013-1020, 2006.
32. L. Klareskog, K. Amara, and V. Malmström, "Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis, " Current Opinion in Rheumatology, vol. 26, no. 1, pp. 72-79, 2014.
33. F. Pratesi, C. Tommasi, C. Anzilotti, D. Chimenti, and P. Migliorini, "Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 54, no. 3, pp. 733-741, 2006.
34. F. Pratesi, C. Tommasi, C. Anzilotti et al., "Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies, " Clinical and Experimental Immunology, vol. 164, no. 3, pp. 337-345, 2011.
35. Z. Szekanecz, L. Soós, Z. Szabó et al., "Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?" Clinical Reviews in Allergy and Immunology, vol. 34, no. 1, pp. 26-31, 2008.
36. R. B. Parekh, D. A. Isenberg, B. M. Ansell, I. M. Roitt, R. A. Dwek, and T. W. Rademacher, "Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity, " The Lancet, vol. 1, no. 8592, pp. 966-969, 1988.
37. J. Keusch, P. M. Lydyard, and P. J. Delves, "The effect on IgG glycosylation of altering β1, 4-galactosyltransferase-1 activity in B cells, " Glycobiology, vol. 8, no. 12, pp. 1215-1220, 1998.
38. S. P. Moyes, C. M. Brown, B. B. Scott, R. N. Maini, and R. A. Mageed, "Analysis of Vκ genes in rheumatoid arthritis (RA) synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection, " Clinical and Experimental Immunology, vol. 105, no. 1, pp. 89-98, 1996.
39. T. Dörner and G. R. Burmester, "The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets, " Current Opinion in Rheumatology, vol. 15, no. 3, pp. 246-252, 2003.
40. G. Cambridge, H. C. Perry, L. Nogueira et al., "The effect of B-cell depletion therapy on serological evidence of Bcell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment, " Journal of Autoimmunity, vol. 50, pp. 67-76, 2014.
41. M. Scarsi, L. Paolini, D. Ricotta et al., "Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis, " The Journal of Rheumatology, vol. 41, no. 4, pp. 666-672, 2014.
42. M. G. Zavala-Cerna, A. Nava, E. García-Castañeda, J. Durán-González, M. J. Arias-Merino, and M. Salazar-Páramo, "Serum IgG activity against cyclic citrullinated peptide in patients evaluated for rheumatoid factor correlates with the IgM isotype, " Rheumatology International, vol. 28, no. 9, pp. 851-857, 2008.
43. A. Greiner, H. Plischke, H. Kellner, and R. Gruber, "Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis, " Annals of the New York Academy of Sciences, vol. 1050, pp. 295-303, 2005.
44. T.D. Jaskowski, H. R.Hill, K. L. Russo, G. Lakos, Z. Szekanecz, and M. Teodorescu, "Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies, " Journal of Rheumatology, vol. 37, no. 8, pp. 1582-1588, 2010.
45. G. Lakos, L. Soós, A. Fekete et al., "Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope, " Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 253-260, 2008.
46. G. A. Schellekens, H. Visser, B. A. de Jong et al., "The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide, " Arthritis & Rheumatism, vol. 43, no. 1, pp. 155-163, 2000.